Genentech to buy Regor’s CDK inhibitors

Roche’s Genentech subsidiary has agreed to pay the biotechnology firm Regor Pharmaceuticals $850 million, plus possible milestone payments, for a portfolio of CDK inhibitors for treating breast cancer. Genentech will be responsible for clinical development, manufacturing, and commercialization; Regor will manage the two ongoing Phase 1 trials.